lists of identified articles were also scanned for relevant papers. There were no language restrictions.
Study selection Randomised controlled trials (RCTs) evaluating OHC in the form of mouthwashes, swabs, toothbrushing or in combination in critically ill patients receiving mechanical ventilation were included.
Data extraction and synthesis Data extraction was carried out independently by two reviewers. Study authors were contracted for additional information. Random-effects meta-analyses were performed where data could be pooled.
Results Thirty-five RCTs (5374 participants) were included. Five trials (14%) were assessed at low risk of bias, 17 studies (49%) were at high risk of bias and 13 studies (37%) were assessed at unclear risk of bias in at least one domain. There were four main comparisons; chlorhexidine (CHX mouthrinse or gel) versus placebo/usual care, toothbrushing versus no toothbrushing, powered versus manual toothbrushing and comparisons of oral care solutions.
Seventeen RCTs (2402 participants, two at high, 11 at unclear and four at low risk of bias) provide moderate quality evidence that CHX mouthrinse or gel, as part of OHC, compared to placebo or usual care is associated with a reduction in VAP (OR 0.60, 95% confidence intervals 
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This review is typically well-conducted, following established
Cochrane methodology. The key finding of this review was that inclusion of chlorhexidine mouthwash or gel as part of the oral health care regime showed a 40% reduction in the odds of developing VAP. This estimate remained very similar when a sensitivity analysis was conducted that excluded the high-risk studies, which found a very similar odds ratio (OR 0.61, 95% CI 0.49 to 0.78, P < 0.001, I 2 = 29%). The body of evidence supporting this was assessed as moderate using the GRADE methodology (Table 1) Toothbrushing versus no toothbrushing did not show a difference in the incidence of VAP (OR 0.69, 95% CI 0.36 to 1.29, P = 0.24).
This finding was very similar to Alhazzani who reported a trend towards lower VAP rates (risk ratio, 0.77; 95% confidence interval, 0.50-1.21; P = 0.26).
While the incidence of VAP was reduced, the available evidence did not reveal any positive effects on the other outcomes of mortality, duration of ventilation, length of stay in ICU, duration of antibiotic use. The authors discuss the mortality issue pointing out that a survival analysis by Bekaert et al. 4 only found an attributable mortality of 1% at 30 days due to VAP, which is likely to explain the review's result.
In conclusion, effective oral care that includes the use of chlorhexidine should be a routine element of care for mechanically ventilated patents in ICU to reduce the incidence of VAP.
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